Pharmacokinetics Study of Epratuzumab in Systemic Lupus Erythematosus (SLE)

Summary

The goal of this study is to evaluate how epratuzumab is processed by the body (pharmacokinetics) and whether 2 dose levels of epratuzumab are safe and effective in patients with SLE.

Timeline

Start

2005-04

Primary completion

2007-03

Completion

2007-06

Publications

• Background Kaufmann J, Wegener WA, Horak ID, et al. Pilot clinical trial of epratuzumab (humanized anti-CD22 antibody) for immunotherapy in systemic lupus erythematosus (SLE) [abstract]. Ann Rheum Dis 2004; 63 (suppl I): Thu0443. (Published online at http://www.eular.org)

Drugs

Indications